345 related articles for article (PubMed ID: 36831572)
1. microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer.
Funamizu N; Honjo M; Tamura K; Sakamoto K; Ogawa K; Takada Y
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831572
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Funamizu N; Lacy CR; Kamada M; Yanaga K; Manome Y
Int J Oncol; 2019 Mar; 54(3):991-1000. PubMed ID: 30628651
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Binenbaum Y; Na'ara S; Gil Z
Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
[TBL] [Abstract][Full Text] [Related]
5. miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer.
Hiramoto H; Muramatsu T; Ichikawa D; Tanimoto K; Yasukawa S; Otsuji E; Inazawa J
Sci Rep; 2017 Jun; 7(1):4002. PubMed ID: 28638102
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
7. Development of microRNA-based therapy for pancreatic cancer.
Fesler A; Ju J
J Pancreatol; 2019 Dec; 2(4):147-151. PubMed ID: 32133215
[TBL] [Abstract][Full Text] [Related]
8. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
[TBL] [Abstract][Full Text] [Related]
9. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Li Y; VandenBoom TG; Kong D; Wang Z; Ali S; Philip PA; Sarkar FH
Cancer Res; 2009 Aug; 69(16):6704-12. PubMed ID: 19654291
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.
Okazaki J; Tanahashi T; Sato Y; Miyoshi J; Nakagawa T; Kimura T; Miyamoto H; Fujino Y; Nakamura F; Takehara M; Ma B; Bando M; Kitamura S; Okamoto K; Muguruma N; Sogabe M; Takayama T
Digestion; 2020; 101(6):794-806. PubMed ID: 31563901
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.
Xiong J; Wang D; Wei A; Ke N; Wang Y; Tang J; He S; Hu W; Liu X
Oncotarget; 2017 Dec; 8(64):107500-107512. PubMed ID: 29296182
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer.
Ye ZQ; Zou CL; Chen HB; Jiang MJ; Mei Z; Gu DN
Dis Markers; 2020; 2020():2782101. PubMed ID: 32566037
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.
Moriyama T; Ohuchida K; Mizumoto K; Yu J; Sato N; Nabae T; Takahata S; Toma H; Nagai E; Tanaka M
Mol Cancer Ther; 2009 May; 8(5):1067-74. PubMed ID: 19435867
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4.
Yu G; Jia B; Cheng Y; Zhou L; Qian B; Liu Z; Wang Y
Am J Transl Res; 2017; 9(11):5048-5055. PubMed ID: 29218103
[TBL] [Abstract][Full Text] [Related]
18. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Xu J; Liu S; Yang X; Cao S; Zhou Y
Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
[TBL] [Abstract][Full Text] [Related]
19. lncRNA GAS5 Reverses EMT and Tumor Stem Cell-Mediated Gemcitabine Resistance and Metastasis by Targeting miR-221/SOCS3 in Pancreatic Cancer.
Liu B; Wu S; Ma J; Yan S; Xiao Z; Wan L; Zhang F; Shang M; Mao A
Mol Ther Nucleic Acids; 2018 Dec; 13():472-482. PubMed ID: 30388621
[TBL] [Abstract][Full Text] [Related]
20. [Pancreatic cancer--mechanisms of chemoresistance].
Borowa-Mazgaj B
Postepy Hig Med Dosw (Online); 2016 Mar; 70():169-79. PubMed ID: 26943314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]